This list is an analysis based on recent market events. It's not an investment recommendation.
About
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
The current price of PLED.STU is €0.98 EUR — it has decreased by -0.2% in the past 24 hours. Watch PledPharma stock price performance more closely on the chart.
What is PledPharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange PledPharma stocks are traded under the ticker PLED.STU.
What is PledPharma market cap?▼
Today PledPharma has the market capitalization of 454.72M
When is the next PledPharma earnings date?▼
PledPharma is going to release the next earnings report on February 25, 2027.
What is PledPharma revenue for the last year?▼
PledPharma revenue for the last year amounts to 5.69M EUR.
What is PledPharma net income for the last year?▼
PLED.STU net income for the last year is -31.27M EUR.
How many employees does PledPharma have?▼
As of November 8, 2026, the company has 56 employees.
In which sector is PledPharma located?▼
PledPharma operates in the Health & Wellness sector.